Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice
Depletion of STAT5 blocks TEL–SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice
复制标题
STAT5 的缺失可阻断 TELâSYK 诱导的小鼠 APMF 型白血病伴骨髓纤维化和骨髓增生异常
DOI:
10.1038/bcj.2014.53
复制
发表时间:
2014
影响因子:
12.8
通讯作者:
Dierks C
中科院分区:
文献类型:
--
作者:
Sprissler C;Belenki D;Maurer H;Aumann K;Pfeifer D;Klein C;Müller TA;Hülsdünker J;Alexandrowski J;Brummer T;Jumaa H;Duyster J;Dierks C
The spleen tyrosine kinase (SYK) was identified as an oncogenic driver in a broad spectrum of hematologic malignancies. The in vivo comparison of three SYK containing oncogenes, SYK wt, TEL–SYK and IL-2-inducible T-cell kinase (ITK)-SYK revealed a general myeloexpansion and the establishment of three different hematologic (pre) diseases. SYK wt enhanced the myeloid and T-cell compartment, without leukemia/lymphoma development. ITK–SYK caused lethal T-cell lymphomas and the cytoplasmic TEL–SYK fusion induced an acute panmyelosis with myelofibrosis-type acute myeloid leukemia (AML) with up to 50% immature megakaryoblasts infiltrating bone marrow, spleen and liver, additional MPN features (myelofibrosis and granulocyte expansion) and MDS stigmata with megakaryocytic and erythroid dysplasia. LKS cells were reduced and all subsets (LT/ST/MPP) showed reduced proliferation rates. SYK inhibitor treatment (R788) of diseased TEL–SYK mice reduced leukocytosis, spleen and liver infiltration, enhanced the hematocrit and prolonged survival time, but could not significantly reduce myelofibrosis. Stat5 was identified as a major downstream mediator of TEL–SYK in vitro as well as in vivo. Consequently, targeted deletion of Stat5 in vivo completely abrogated TEL–SYK-induced AML and myelofibrosis development, proving Stat5 as a major driver of SYK-induced transformation. Our experiments highlight the important role of SYK in AML and myelofibrosis and prove SYK and STAT5 inhibitors as potent treatment options for those diseases.
登录
查看更多内容
DOI:
10.1084/jem.20092042
发表时间:
2010-05-10
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Pechloff K;Holch J;Ferch U;Schweneker M;Brunner K;Kremer M;Sparwasser T;Quintanilla-Martinez L;Zimber-Strobl U;Streubel B;Gewies A;Peschel C;Ruland J
通讯作者:
Ruland J
影响因子:
20.3
作者:
M. Cavazzana‐Calvo;C. Lagresle;E. Six;C. Picard;F. Rieux;Vincent Michel;Andrea Ditadi;Corinne Demerens;E. Morillon;F. Valensi;K. Simon;J. Mullikin;L. Noroski;C. Besse;N. Wulffraat;A. Ferster;M. Abecasis;F. Calvo;C. Petit;F. Candotti;L. Abel;A. Fischer
通讯作者:
A. Fischer
DOI:
--
发表时间:
--
期刊:
--
影响因子:
--
作者:
通讯作者:
--
影响因子:
15.3
作者:
S. Yousefi;D. Hoessli;K. Blaser;G. Mills;H. Simon
通讯作者:
H. Simon
DOI:
--
发表时间:
1994
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Chan,AC;vanOers,NS;Tran,A;Turka,L;Law,CL;Ryan,JC;Clark,EA;Weiss,A
通讯作者:
Weiss,A